SCHEMBL23924233

SCHEMBL23924233

O=C(Nc1cccc2c(Cl)nccc12)[C@H]1CN(C(=O)O)C[C@@H]1c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
FABP7 O15540 2/20 0.37
NAMPT P43490 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TLR2 O60603 3/20 0.36
TLR1 Q15399 3/20 0.36
FABP3 P05413 1/20 0.35
P2RX7 Q99572 1/20 0.35
CYP2C19 P33261 2/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
TSHR P16473 1/20 0.34
KMT2A Q03164 1/20 0.34
DEGS1 O15121 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23924412 0.88 KDM4E (0.38) KDM4EFABP7NAMPTALDH1A1LMNA
SCHEMBL23924411 0.88 KDM4E (0.38) KDM4EFABP7NAMPTALDH1A1LMNA
SCHEMBL23951748 0.87 TACR1 (0.51) POLBTACR1
SCHEMBL29900751 0.85 MC1R (0.44) KDM4EFABP7NAMPTALDH1A1LMNA
SCHEMBL23924015 0.83 ALDH1A1 (0.48) KDM4EALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL23924016 0.83 ALDH1A1 (0.48) KDM4EALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL23924250 0.82 FABP7 (0.55) KDM4EFABP7ALDH1A1LMNAGAA
SCHEMBL23924238 0.82 FABP7 (0.55) KDM4EFABP7ALDH1A1LMNAGAA
SCHEMBL23924239 0.82 FABP7 (0.55) KDM4EFABP7ALDH1A1LMNAGAA
SCHEMBL23951287 0.81 ROCK2 (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 KDM4E 2961/4885FABP7 666/4885NAMPT 279/4885
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 KDM4E 2961/4885FABP7 666/4885NAMPT 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.